Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3347
Name osteosarcoma
Definition A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus).
Source DiseaseOntology.org
Alt Ids DOID:183
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma osteosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 R280M Nutlin-3a osteosarcoma resistant detail...
TP53 I232S Nutlin-3a osteosarcoma resistant detail...
TP53 E258Q Nutlin-3a osteosarcoma resistant detail...
TP53 P177T Nutlin-3a osteosarcoma resistant detail...
RB1 wild-type TP53 mut R547 osteosarcoma sensitive detail...
TP53 wild-type CPUY201112 osteosarcoma sensitive detail...
TP53 loss CPUY201112 osteosarcoma decreased response detail...
RB1 mutant VCN-01 osteosarcoma sensitive detail...
TP53 wild-type KRT-232 osteosarcoma sensitive detail...
TP53 wild-type KRT-232 + Radiotherapy osteosarcoma sensitive detail...
TP53 mutant N/A osteosarcoma not applicable detail...
PTEN loss MK2206 osteosarcoma sensitive detail...
PTEN loss Sirolimus osteosarcoma sensitive detail...
BRAF G469V Trametinib osteosarcoma no benefit detail...
MLH1 negative Pembrolizumab osteosarcoma sensitive detail...
MSH6 negative Pembrolizumab osteosarcoma sensitive detail...
RAD51C T132R Olaparib osteosarcoma sensitive detail...
RAD51C K131I Olaparib osteosarcoma sensitive detail...
RAD51C G130R Olaparib osteosarcoma sensitive detail...
RAD51C R168G Olaparib osteosarcoma sensitive detail...
TSC2 mutant Temsirolimus osteosarcoma no benefit detail...
TSC2 mutant Irinotecan + Temozolomide + Temsirolimus osteosarcoma no benefit detail...
EML4 - ALK Alectinib osteosarcoma predicted - sensitive detail...
EML4 - ALK Lorlatinib osteosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00902044 Phase I Fludarabine Cyclophosphamide HER2 sensitized T-cells Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Active, not recruiting USA 0
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed USA 0
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01759303 Phase II Pazopanib Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung Terminated USA 0
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed USA | SVK | HUN | FRA | ESP | CZE | CAN 0
NCT02013336 Phase I Cyclophosphamide + Liposomal irinotecan Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Unknown status USA 0
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Completed USA 0
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Completed USA 0
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT02357810 Phase II Pazopanib + Topotecan Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Completed USA 0
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT02406781 Phase II Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) Unknown status FRA 0
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting USA 0
NCT02470091 Phase II Denosumab Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Completed USA | CAN 1
NCT02487979 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Completed USA | CAN 1
NCT02517918 Phase I Cyclophosphamide + Methotrexate + Sirolimus + Zoledronic acid Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma a (METZOLIMOS) Completed FRA 0
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Unknown status CAN 0
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed USA 0
NCT03006848 Phase II Avelumab A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Completed USA 0
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Completed USA 0
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03242382 Phase II Palbociclib Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) Recruiting ESP 0
NCT03277924 Phase Ib/II Nivolumab + Sunitinib Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) Completed ITA | GBR | ESP 0
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting USA 0
NCT03320330 Phase Ib/II Pepinemab VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Completed USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU | CHE 1
NCT03449108 Phase II Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Active, not recruiting USA 0
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03628209 Phase Ib/II Azacitidine + Nivolumab Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Active, not recruiting USA 0
NCT03635632 Phase I C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Completed USA 0
NCT03811886 Phase Ib/II Natalizumab Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma Recruiting USA 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT03900793 Phase I Losartan + Sunitinib Losartan + Sunitinib in Treatment of Osteosarcoma Recruiting USA 0
NCT03960177 Phase I Glucarpidase Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma Active, not recruiting USA 0
NCT04040205 Phase II Abemaciclib Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Recruiting USA 0
NCT04055220 FDA approved Regorafenib Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) Recruiting FRA 0
NCT04154189 Phase II Etoposide + Ifosfamide Etoposide + Ifosfamide + Lenvatinib A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma Completed USA | SWE | NZL | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS 4
NCT04183062 Phase II BIO-11006 + Docetaxel + Gemcitabine BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases Withdrawn USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04417062 Phase II Ceralasertib + Olaparib Olaparib With Ceralasertib in Recurrent Osteosarcoma Recruiting USA 0
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Recruiting USA 0
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Recruiting HUN | GBR | FRA | ESP | DEU | CZE 0
NCT04595994 Phase I Selinexor Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Recruiting ESP 0
NCT04616560 Phase II Trastuzumab deruxtecan Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma Suspended USA 0
NCT04661852 Phase I Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan Cabozantinib With Topotecan-Cyclophosphamide Completed USA 0
NCT04668300 Phase II Durvalumab + Oleclumab Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) Recruiting USA 0
NCT04698785 Phase II Regorafenib Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN) Recruiting FRA 0
NCT04751383 Phase I Dinutuximab + Hu5F9-G4 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Active, not recruiting USA | CAN 0
NCT04758000 Phase II Metformin Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse (Metform-Bone) Recruiting ITA 0
NCT04784247 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04803877 Phase II Nivolumab + Regorafenib SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Active, not recruiting USA 0
NCT04833582 Phase Ib/II Gemcitabine + ZN-c3 A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma Active, not recruiting USA | FRA 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04870944 Phase Ib/II CBL0137 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Recruiting USA | AUS 0
NCT04897880 Phase II Panobinostat A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) Terminated USA | NZL | AUS 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT04974008 Phase II ADXS31-164 Osteosarcoma Maintenance Therapy With OST31-164 (OST-164-01) Completed USA 0
NCT05019703 Phase II Atezolizumab + Cabozantinib Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Recruiting USA 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05182164 Phase II Cabozantinib + Pembrolizumab Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) Recruiting FRA 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05302921 Phase II Ipilimumab + Nivolumab Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Active, not recruiting USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05395741 Phase Ib/II Regorafenib Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone) Recruiting POL 0
NCT05588648 Phase Ib/II Vactosertib Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Recruiting USA 1
NCT05621668 Phase I AttIL12 T-cells + Cyclophosphamide A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Recruiting USA 0
NCT05691478 Phase II Cisplatin + Doxorubicin + Methotrexate Doxorubicin + Methotrexate Cabozantinib Cabozantinib + Cisplatin + Doxorubicin + Methotrexate Cabozantinib + Doxorubicin + Methotrexate A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Suspended USA 0
NCT05703854 Phase Ib/II CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Recruiting USA 0
NCT05726383 Phase II Mistletoe extract Immunotherapy for Recurrent Osteogenic Sarcoma Recruiting USA 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT06156410 Phase I Cabozantinib + Ifosfamide Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Recruiting USA 0
NCT06341712 Phase II Cabozantinib Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma (CabOSTar) Recruiting USA | SWE | POL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT 0
NCT06474676 Phase I AttIL12 T-cells Cyclophosphamide T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. Not yet recruiting USA 0
NCT06492954 Phase I Atezolizumab Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma (AflacST2301) Recruiting USA 0
NCT06521567 Phase Ib/II Cobolimab + Dostarlimab-gxly A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Not yet recruiting USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG 1
NCT06541262 Phase Ib/II Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors Recruiting USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0